Correlation of p27 protein expression with HER-2/neu expression in breast cancer

Molecular Carcinogenesis

Volumn 30, Issue 3, 2001, Pages 169-175

  Newman, Lisa ^a   Xia, Weiya ^a   Yang, Heng Yin ^a   Sahin, Aysegal ^a   Bondy, Melissa ^a   Lukmanji, Farzana ^a   Hung, Mien Chie ^a   Lee, Mong Hong ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Human epidermal growth factor receptor 2 neu; P27Kip1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CARCINOMA IN SITU; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME INHIBITORS; FEMALE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEINS;

EID: 0035065282     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.1025     Document Type: Article

References (39)

1. HER-2/neu-targeting gene therapy
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
6. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
7. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
8. Inhibitors of mammalian G1 cyclin-dependent kinases
9. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
10. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin
11. New insights into the tumor suppression function of P27(kip1)
12. The murine gene p27Kip1 is haplo-insufficient for tumour suppression
13. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
14. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
15. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma
16. p27 expression and gastric carcinoma
17. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
18. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: Inverse correlation with disease-free survival
19. Increased proteasomedependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
20. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer
21. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
22. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
23. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
24. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
25. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
26. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma
27. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
28. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas
29. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
30. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27
31. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex
32. Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus
33. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins
34. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors
35. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1
36. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
37. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
38. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
39. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225